Glaucoma Pharmaceuticals (MCP-6268) - Global Industry Analysts, Inc.

Research Abstract

This report analyzes the Global market for Glaucoma Pharmaceuticals in US$ Million. The report provides separate comprehensive analytics for US, and Rest of World. Annual forecasts are provided for the period 2006 through 2015. The report profiles 32 companies including many key and niche players worldwide such as Acadia Pharmaceuticals, Inc., Alcon Laboratories, Inc., Allergan, Inc., Falcon Pharmaceuticals, Ltd., Inotek Pharmaceuticals Corporation, Inspire Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Inc., NicOx S.A, Novartis International AG , Pfizer, Inc., and Santen Pharmaceutical Co., Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Code :	MCP-6268
Price :	$3950
Companies :	32

Pages :	260
Date :	February 2010
Market Data Tables :	75

Complimentary Market Brief:

Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.

GLAUCOMA PHARMACEUTICALS (Complete Report)

Pages : 260

$3950

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

$100

Study Reliability and Reporting Limitations.....I-1

Disclaimers.....I-2

Data Interpretation & Reporting Level.....I-3

Quantitative Techniques & Analytics.....I-3

Product Definitions and Scope of Study.....I-3

II. EXECUTIVE SUMMARY

$2250

1. GLOBAL OUTLOOK.....II-1

$700

Rising Incidences of Glaucoma Demands Novel Medications.....II-1

Understanding of Treatment Patterns Imperative for Developing New Drugs.....II-1

How Widespread is the Disease?.....II-1

$100

Table 1: Worldwide Glaucoma Prevalence by Select Countries (includes corresponding Graph/Chart).....II-2

Aging Population & Environmental Factors Drive Growth.....II-2

$300

Combination Drugs Become Mainstay Glaucoma Products.....II-3

Is Marijuana A Potential Cure?.....II-3

Lack of Awareness Among Patients – A Prevailing Trend.....II-3

$100

High Costs Discourage Patients from Receiving Treatment.....II-4

The All-Consuming Issue of Compliance.....II-4

Competitive Landscape.....II-4

$100

Table 2: Global Market for Glaucoma Pharmaceuticals (2008): Percentage Value Share Breakdown of Leading Players - Pfizer, Inc., Allergan, Inc., Merck & Co., Alcon, Ista Pharmaceuticals and Others (includes corresponding Graph/Chart).....II-5

Current and Future Analysis.....II-5

$300

2. AN OVERVIEW OF GLAUCOMA DISORDER.....II-6

$300

A Prelude.....II-6

Who’s At Risk?.....II-6

Leading Causes for Glaucoma.....II-6

Diagnosis.....II-6

$100

Symptom Free Progression: A Major Concern.....II-7

Types of Glaucoma.....II-7

$100

Primary Glaucoma.....II-8

Primary Open-Angle Glaucoma (POAG).....II-8

Acute Angle-Closure Glaucoma (AACG).....II-8

$100

Developmental Glaucoma.....II-9

Secondary Glaucoma.....II-9

Other Common Types of Glaucoma.....II-9

Pigmentary Glaucoma.....II-9

Pseudo-Exfoliation Glaucoma.....II-9

$100

Neovascular Glaucoma.....II-10

Toxic Glaucoma.....II-10

$100

3. AN OVERVIEW OF GLAUCOMA TREATMENT.....II-11

$700

Glaucoma Treatment Strategies.....II-11

Drugs Used for Treating Glaucoma.....II-11

$100

A Quick Look at Major Drugs by Category.....II-12

Beta-Adrenergic Blockers or "Beta Blockers".....II-12

Profile of Major Drugs under the Category.....II-12

Timolol.....II-12

Levobunolol.....II-12

Carteolol.....II-12

$100

Metipranolol.....II-13

Betaxolol.....II-13

Side Effects of Beta-Blockers.....II-13

Alpha-Adrenergic Agonists.....II-13

$100

Side Effects of Alpha-Adrenergic Agonists.....II-14

Carbonic Anhydrase Inhibitors.....II-14

Profile of Major Drugs under the Category.....II-14

Acetazolamide.....II-14

Dorzolamide.....II-14

$100

Side Effects of Carbonic Anhydrase Inhibitors.....II-15

Prostaglandin Analogues.....II-15

Side Effects of Prostaglandin Analogues.....II-15

$100

Miotics.....II-16

Side Effects of Miotics.....II-16

Epinephrine Compounds.....II-16

Mydriatics & Cycloplegics.....II-16

Commercial Mydriatic-Cycloplegics.....II-16

$100

Side Effects of Mydriatic-Cycloplegics.....II-17

Neuroprotective Drugs.....II-17

Surgical Approach to Glaucoma Treatment.....II-17

Laser Surgery.....II-17

$100

Laser Trabeculoplasty.....II-18

Argon Laser Trabeculoplasty (ALT).....II-18

Selective Laser Trabeculoplasty (SLT).....II-18

Laser Peripheral Iridotomy (LPI).....II-18

Filtering Procedure.....II-18

$100

Trabeculectomy.....II-19

Drainage Implant Surgery.....II-19

Other Surgical Procedures.....II-19

Non-Penetrating Surgery.....II-19

Canaloplasty.....II-19

$100

The Express Mini Glaucoma Shunt.....II-20

Trabectome.....II-20

$100

4. SELECT NEW DRUG APPROVALS.....II-21

$300

Novagali Obtains FDA Approval for Catioprost Phase III Trial.....II-21

X-Gen Obtains FDA Approval for Acetazolamide Injection.....II-21

Alcon Obtains EMEA Approval for Azarga® Ophthalmic Suspension.....II-21

$100

Santen Receives Clearance for Tapros™ in Japan.....II-22

Santen Obtains Marketing Clearance for Taflotan™ in Denmark.....II-22

Allergan Obtains FDA Clearance for Combigan.....II-22

$100

Alcon Receives Japanese Approval for Travatanz™ Solution.....II-23

$100

5. RECENT INDUSTRY ACTIVITY.....II-24

$400

Alcon to Take Over Swiss Biotech Company, ESBATech.....II-24

Abbott Acquires Advanced Medical Optics.....II-24

Aton Pharma Purchases US Marketing Rights to Merck 's Timoptic.....II-24

$100

NicOx to Re-Acquire Rights to Glaucoma Drug from Pfizer.....II-25

Merck Inks Licensing Deal for Tafluprost with Santen.....II-25

$100

Sucampo Inks In-licensing Deal with R-Tech for Rescula.....II-26

Alcon Commences Construction of Pharmaceutical Manufacturing Facility.....II-26

Alcon Abandons Anecortave Acetate Development.....II-26

$100

Pipex to Acquire Rights to Additional Usage of Oral Flupirtine.....II-27

Othera Submits IND Application with FDA for OT-730.....II-27

Inspire Commences Phase I Trial of Glaucoma Candidate, INS117548.....II-27

$100

Lexicon Begins Preclinical Development of LX7101 for Glaucoma.....II-28

Pipex Pharmaceuticals Changes Name to Adeona Pharmaceuticals.....II-28

Warburg Pincus Acquires Bausch & Lomb.....II-28

Santen and R-Tech Extend Marketing Agreement for RESCULA® in Japan.....II-28

$200

6. FOCUS ON SELECT GLOBAL PLAYERS.....II-30

$400

Acadia Pharmaceuticals, Inc. (US).....II-30

Alcon Laboratories, Inc. (US).....II-30

$100

Allergan, Inc. (US).....II-31

Falcon Pharmaceuticals, Ltd. (US).....II-31

$100

Inotek Pharmaceuticals Corporation (US).....II-32

Inspire Pharmaceuticals, Inc. (US).....II-32

$100

Lexicon Pharmaceuticals, Inc. (US).....II-33

Merck & Co., Inc. (US).....II-33

NicOx S.A. (France).....II-33

$100

Novartis International AG (Switzerland).....II-34

Pfizer, Inc. (US).....II-34

$100

Santen Pharmaceutical Co., Ltd. (Japan).....II-35

$100

7. GLOBAL MARKET PERSPECTIVE.....II-36

Table 3: World Recent Past, Current & Future Analysis for Glaucoma Pharmaceuticals Market by Geographic Region – US and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-36

Table 4: World 10-year Perspective for Glaucoma Pharmaceuticals Market by Geographic Region – Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2006, 2009 & 2015.....II-36

$300

III. MARKET

$1950

1. THE UNITED STATES.....III-1

$1275

A. Market Analysis.....III-1

Glaucoma Market: A Quick Primer.....III-1

$75

Table 5: Glaucoma Pharmaceutical Products Prescription Volume in the US (2008 & 2009): Percentage Breakdown for Xalatan, Lumigan, Alphagan P, Travatan and Others (includes corresponding Graph/Chart).....III-2

Prevalence of Glaucoma – A Recapitulation of Facts.....III-2

Patent Expiries to Prune Glaucoma Market Size.....III-2

$150

Patent Expiries of Key Glaucoma Drugs in Recent Past, Current, and Future.....III-3

Leading Drugs to Lose Sheen.....III-3

$75

Table 6: Leading Glaucoma Pharmaceutical Products in the US (2008, 2010 & 2012): Percentage Breakdown of Value Sales for Xalatan/Xalcom, Cosopt, Lumigan, Travatan, Alphagan, Combigan, Generic Timolol and Others (includes corresponding Graph/Chart).....III-4

Research & Development.....III-4

Select Combination Therapeutics in Pipeline.....III-4

Ganfort (Lumigan/timolol) – Pending Approval.....III-4

$150

DuoTrav (Travatan/timolol) – Pending Approval.....III-5

Xalcom (Xalatan/timolol) – Pending Approval.....III-5

Azopt (brinzolamide/timolol) – Phase III.....III-5

Travatan/Azopt – Phase III.....III-5

Pipeline Directory of Glaucoma Pharmaceuticals in the US (As of March 2009).....III-5

Select Glaucoma Pharmaceuticals in Phase III Clinical Studies.....III-5

$75

Select Glaucoma Pharmaceuticals in Phase II Clinical Studies.....III-6

Select Glaucoma Pharmaceuticals in Phase I Clinical Studies.....III-6

Select New Drug Approvals.....III-6

$75

Strategic Corporate Developments.....III-7

$300

Select Players in the Region.....III-11

$375

B. Market Analytics.....III-16

Table 7: US Recent Past, Current & Future Analysis for Glaucoma Pharmaceuticals Market by Drug Class – Alpha Adrenergic Agonists, Beta-Blockers, Carbonic Anhydrase Inhibitors, Combination Therapies, Prostaglandin Analogues and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-16

$150

Table 8: US 10-Year Perspective for Glaucoma Pharmaceuticals by Drug Class – Percentage Breakdown of Dollar Sales for Alpha Adrenergic Agonists, Beta-Blockers, Carbonic Anhydrase Inhibitors, Combination Therapies, Prostaglandin Analogues and Other Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-17

$150

2. REST OF WORLD.....III-18

$650

A. Market Analysis.....III-18

Combination Drugs and Generics to Gain Traction.....III-18

$75

Table 9: Leading Glaucoma Pharmaceutical Products in Rest of World Market (2008, 2010 & 2012): Percentage Breakdown of Value Sales for Xalatan/Xalcom, Cosopt/Trusopt, Travatan/Extravan, Lumigan/ Ganfort, Alphagan/Combigan, Timoptic/ XE, Generic Timolol and Others (includes corresponding Graph/Chart).....III-19

Focus on Glaucoma Market in Select Countries.....III-19

CANADA.....III-19

Lack of Awareness: A Key Issue.....III-19

$150

EUROPE.....III-20

Glaucoma Pharmaceuticals Reimbursement in Europe.....III-20

$75

CHINA.....III-21

Select Drug Approvals.....III-21

$150

Strategic Corporate Developments.....III-23

$75

Select Players.....III-24

$150

B. Market Analytics.....III-26

Table 10: Rest of World Recent Past, Current & Future Analysis for Glaucoma Pharmaceuticals – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-26

$150

IV. COMPETITIVE LANDSCAPE

186

$995

Total Companies Profiled: 32 (including Divisions/Subsidiaries - 33)
Region/Country                 Players

The United States                 20   
Canada                             1 
Japan                              4
Europe                             7
     France                        3
     Rest of Europe                4
Middle East                        1

Click here to request a full table of contents and more details on this project.

GLAUCOMA PHARMACEUTICALS - A GLOBAL MARKET REPORT

Research Abstract

Complimentary Market Brief:

TABLE OF CONTENTS

GLAUCOMA PHARMACEUTICALS - A GLOBAL MARKET REPORT stLight.options({ publisher:'12345' });

Research Abstract

Complimentary Market Brief:

TABLE OF CONTENTS

GLAUCOMA PHARMACEUTICALS - A GLOBAL MARKET REPORT